Cellosaurus logo
expasy logo
Due to maintenance work, this service will be unavailable from Mon Nov 11 17:30 until Tue Nov 12 09:00 CET. Apologies for the inconvenience.

Cellosaurus LoVo_6244R (CVCL_C3GL)

[Text version]
Cell line name LoVo_6244R
Synonyms L6244-R
Accession CVCL_C3GL
Resource Identification Initiative To cite this cell line use: LoVo_6244R (RRID:CVCL_C3GL)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244).
Omics: Transcriptome analysis by RNAseq.
Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
Sequence variations
  • Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line).
Disease Colon adenocarcinoma (NCIt: C4349)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0399 (LoVo)
Sex of cell Male
Age at sampling 56Y
Category Cancer cell line
Publications

PubMed=31048689; DOI=10.1038/s41467-019-09438-w; PMCID=PMC6497655
Sale M.J., Balmanno K., Saxena J., Ozono E., Wojdyla K., McIntyre R.E., Gilley R., Woroniuk A., Howarth K.D., Hughes G., Dry J.R., Arends M.J., Caro P., Oxley D., Ashton S., Adams D.J., Saez-Rodriguez J., Smith P.D., Cook S.J.
MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF(V600E) amplification whereas KRAS(G13D) amplification promotes EMT-chemoresistance.
Nat. Commun. 10:2030.1-2030.22(2019)

Cross-references
Cell line databases/resources cancercelllines; CVCL_C3GL
Encyclopedic resources Wikidata; Q114311891
Gene expression databases GEO; GSM3591766
Entry history
Entry creation22-Sep-2022
Last entry update05-Oct-2023
Version number5